Neoadjuvant Treatment for Resectable Cancer of the Esophagus and the Gastroesophageal Junction: A Meta-Analysis of Randomized Clinical Trials
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Background: There is no general agreement on the effect of neoadjuvant treatment for esophageal cancer on patient survival.
Methods: A meta-analysis was performed to determine the effect of preoperative treatment on survival of patients with resectable esophageal cancer and the effect of preoperative treatment on patient mortality. A standard variance-based method was used to derive summary estimates of the absolute difference in both 2-year survival and treatment-related mortality.
Results: Eleven randomized trials involving 2311 patients were analyzed. Preoperative chemotherapy improved 2-year survival compared with surgery alone: the absolute difference was 4.4% (95% confidence interval [CI], .3%–8.5%). Marginal evidence of heterogeneity was eliminated by restricting attention to the four most recent studies, which increased the estimate to 6.3% (95% CI, 1.8%–10.7%). For combined chemoradiotherapy, the increase was 6.4% (nonsignificant; 95% CI, −1.2%–14.0%). Treatment-related mortality increased by 1.7% with neoadjuvant chemotherapy (95% CI, −.9%—4.3%) and by 3.4% with chemoradiotherapy (95% CI, −.1%–7.3%), compared with surgery alone.
Conclusions: There seems to be a modest survival advantage for patients who receive neoadjuvant chemotherapy followed by surgery, as compared with surgery alone. There is an apparent increase in treatment-related mortality, mainly for patients who receive neoadjuvant chemoradiotherapy.
- Jemal A, Thomas A, Murray T, et al. Cancer statistics 1999. CA Cancer J Clin 2002; 52: 23–47. CrossRef
- Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287–9. CrossRef
- Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104: 510–3.
- Daly JM, Fry WA, Little AG, et al. Esophageal cancer: results of an American College of Surgeon Patient Care evaluation study. J Am Coll Surg 2000; 190: 562–73. CrossRef
- Ellis FH Jr, Heatley GJ, Krasna MJ, et al. Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. J Thorac Cardiovasc Surg 1997; 113: 836–46. CrossRef
- Mueller JM, Erasmi H, Stelzner M, et al. Surgical therapy of esophageal carcinoma. Br J Surg 1990; 77: 845–57. CrossRef
- Newaishiy GA, Read GA, Duncan W, et al. Results of radical radiotherapy of squamous cell carcinoma of the esophagus. Clin Radiol 1982; 33: 347–52. CrossRef
- Stewart JR, Hoff SJ, Johnson DH, et al. Improved survival with neoadjuvant therapy and resection for adenocarcinoma of the esophagus. Ann Surg 1993; 218: 571–6. CrossRef
- Vogel SB, Mendelhall WM, Sombeek MD, et al. Downstaging esophageal cancer after preoperative radiation and chemotherapy. Ann Surg 1995; 221: 685–95. CrossRef
- Collett D. Modeling Survival in Medical Research. London: Chapman & Hall, 1994: 25–6.
- Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815–34. CrossRef
- Petitti DB. Meta-Analysis, Decision Analysis and Cost-Effectiveness Analysis. Methods for Quantitative Synthesis in Medicine. New York: Oxford University Press, 2000: 107–16.
- Gignoux M, Roussel A, Paillot B, et al. The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C. World J Surg 1987; 11: 426–32. CrossRef
- Launois B, Delarue D, Campion JP, et al. Preoperative radiotherapy for carcinoma of the esophagus. Surg Gynecol Obstet 1981; 153: 690–2.
- Wang M, Gu XZ, Yin WB, Huang GJ, Wang LJ, Zhang DW. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients. Int J Radiat Oncol Biol Phys 1988; 16: 325–7.
- Arnott SJ, Duncan W, Kerr GR, et al. Low dose preoperative radiotherapy for carcinoma of the esophagus: results of a randomized clinical trial. Radiother Oncol 1992; 24: 108–13. CrossRef
- Wright CD, Mathisen DJ, Wain JC, et al. Evolution of treatment strategies for adenocarcinoma of the esophagus and gastroesophageal junction. Ann Thorac Surg 1994; 58: 1574–8. CrossRef
- Arnott SJ, Duncan W, Gignoux M, et al. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). Int J Radiat Oncol Biol Phys 1998; 41: 579–83. CrossRef
- Orringer MB. Multimodality therapy for esophageal carcinoma-update. Chest 1993; 103 (Suppl 4): 406S–409S. CrossRef
- Murthy SK, Prabhakaran PS, Chandrashekar M, Deshpande R, Doval DC, Gopinath KS. Neoadjuvant Cis-DDP in esophageal cancers: an experience at a regional cancer centre, India. J Surg Oncol 1994; 45: 173–6. CrossRef
- Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985; 312: 1604–8. CrossRef
- Heath EI, Burtness BA, Heitmiller RF, et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 2000; 18: 868–76.
- Seydel HG, Leichman L, Byhardt R, et al. Preoperative radiation and chemotherapy for localized squamous cell carcinoma of the esophagus: a RTOG study. Int J Radiat Oncol Biol Phys 1988; 14: 33–5.
- Forastiere AA, Orringer MB, Perez-Tamayo C, et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol 1993; 6: 1118–23.
- Bates BA, Detterbeck FC, Bernard SA, et al. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol 1996; 14: 156–63.
- Keller SM, Ryan LM, Coia LR, et al. High dose chemo-radiotherapy followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction. Results of a phase II study of the Eastern Cooperative Oncology Group. Cancer 1998; 83: 1908–16. CrossRef
- Neoadjuvant Treatment for Resectable Cancer of the Esophagus and the Gastroesophageal Junction: A Meta-Analysis of Randomized Clinical Trials
Annals of Surgical Oncology
Volume 10, Issue 7 , pp 754-761
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Esophageal cancer
- Industry Sectors
- Author Affiliations
- 1. Division of Surgical Oncology, Sylvester Cancer Center, University of Miami, Miami, Florida
- 2. Division of Biostatistics, Sylvester Cancer Center, University of Miami, Miami, Florida
- 3. University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Division of Surgical Oncology (310T), 1475 NW 12th Avenue, Room 3550, Miami, FL, 33136